Lv63
2109 积分 2023-03-30 加入
An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
2天前
已完结
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
2天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
5天前
已完结
Perioperative Toripalimab in Stage III Non–Small Cell Lung Cancer
15天前
已关闭
Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis
15天前
已关闭
Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer
16天前
已完结
Claudin proteins as emerging therapeutic targets for solid tumours
16天前
已完结
Azenosertib in combination with bevacizumab as maintenance therapy in patients with advanced ovarian cancer: part 2 of a phase 1b study
19天前
已关闭
Targeting cytokines: Reshaping the pancreatic tumor microenvironment
26天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
29天前
已完结
皖公网安备34019202002308
